Bioverativ (Bioverativ) Short-Term Capital Lease Obligation : $0 Mil (As of Dec. 2017)

View and export this data going back to 2017. Start your Free Trial

What is Bioverativ Short-Term Capital Lease Obligation?

Bioverativ's Short-Term Capital Lease Obligation for the quarter that ended in Dec. 2017 was $0 Mil.

Bioverativ Short-Term Capital Lease Obligation Historical Data

The historical data trend for Bioverativ's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioverativ Short-Term Capital Lease Obligation Chart

Bioverativ Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Short-Term Capital Lease Obligation

Bioverativ Quarterly Data
	Dec13	Dec14	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial							-	-	-	-	-

Bioverativ Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Bioverativ Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Bioverativ's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioverativ (Bioverativ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioverativ Inc (NAS:BIVV) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.bioverativ.com

Bioverativ Inc is a biotech focused on rare blood disorders and has two marketed hemophilia products: Eloctate (hemophilia A) and Alprolix (hemophilia B). Bioverativ spun off from Biogen in February 2017. Bioverativ's partner Swedish Orphan Biovitrum holds rights to these therapies and pipeline hemophilia therapies in many markets outside the U.S. Bioverativ is building a pipeline in rare blood-related disorders, such as TNT009 (part of the True North acquisition) in cold agglutinin disease and other hematology-focused drug candidates. Sanofi's pending acquisition of Bioverativ was announced in January 2018.

Executives

Alexander J Denner	director	C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Brian S Posner	director	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
John Cox	director, officer: Chief Executive Officer	C/O BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
John Greene	officer: EVP, CFO and Treasurer	51 LIME STREET, LONDON X0 EC3M 7DQ
Geno J Germano	director	5 GIRALDA FARMS, MADISON NJ 07940
Louis J Paglia	director	C/O UIL HOLDINGS CORP, 157 CHURCH STREET, NEW HAVEN CT 06506
Anna Protopapas	director	MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Diantha Duvall	officer: Chief Accounting Officer	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Vivaldi Coelho Rogerio	officer: EVP, Chief Global Therapeutics	225 SECOND AVENUE, WALTHAM MA 02451
Harris Timothy J.r.	officer: EVP, R & D	C/O BG MEDICINE, 610 LINCOLN STREET NORTH, WALTHAM MA 02451
Lucia Celona	officer: EVP, HR & Corp Commun. Officer	BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Richard Brudnick	officer: EVP, Business Development	BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Biogen Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142

Bioverativ (Bioverativ) Headlines

From GuruFocus

Jeff Ubben Buys 1, Sells 1 in 1st Quarter

By Sydnee Gatewood Sydnee Gatewood • 05-24-2017

Seeking Value in Biotech: Bioverativ

By Mark Yu Mark Yu • 06-29-2017

5 Companies Hit 52-Week Highs

By yifan900 yifan900 • 05-29-2018